Rapid Nutrition Q3 Revenue Hits $1M Monthly, Up 1,000%

Rapid Nutrition PLC (Euronext Growth Paris: ALRPD) said on 29 September 2026 that unaudited management information points to average Group revenue of roughly $1 million per month for the three months ended 30 September 2026, a figure the company described as more than 1,000% above its average monthly Group revenue in FY2025. The company called the quarter a record. Management framed the result as the payoff from an accelerated growth strategy and the larger operating base built during the first half of the year.

Context — why the Q3 revenue milestone matters now

Rapid Nutrition built its operating footprint through the first half of 2026, and management told the market at the time that the added scale would eventually show up in revenue. The Q3 update is the company's own confirmation that the conversion has begun.

The comparable the company supplies is its FY2025 average monthly Group revenue, the baseline against which the 1,000% growth figure is calculated. Rapid Nutrition did not publish the absolute FY2025 monthly average, so the dollar base behind that percentage remains undisclosed.

The company operates five wellness hubs that give it an established presence in the Australian domestic market and direct engagement with wellness customers. Those hubs sit alongside existing brands, digital capabilities and distribution channels.

Management's stated priorities are to strengthen operations across the group, push SystemLS® and other proprietary products through its available channels, and develop practitioner-led services delivered via the hubs.

Simon St Ledger, Managing Director, said the company "deliberately established the operating foundations to support lasting and scalable growth" and that the work is now flowing through to group revenue. He also called the quarter an important milestone.

Rapid Nutrition positions itself as a HealthTech and wellness company built on evidence-based nutrition and personalized wellness, using artificial intelligence, advanced technologies and clinical research.

Data — what the numbers show

The headline figure is the average: approximately $1 million per month across Q3 2026, covering July through September. The comparison is a percentage, not a dollar level.

Metric	Value
Q3 2026 average monthly Group revenue	~$1 million
Change vs FY2025 monthly average	more than +1,000%
Period covered	three months ended 30 September 2026
Basis	unaudited management information
Currency	Australian dollars unless otherwise stated

On a before-and-after basis, the company's own framing is that revenue has moved from a FY2025 monthly average to roughly $1 million per month in Q3 2026, a step change of more than ten times.

The report gives no absolute revenue total for the quarter, no FY2025 monthly dollar figure, no margin, no profit line and no cash balance. It also gives no revenue split by hub, brand or geography.

The company said the revenue information remains subject to finalisation, and that the percentage comparison is against average monthly Group revenue for FY2025. All monetary amounts are expressed in Australian dollars unless otherwise stated.

No peer or sector comparison appears in the report, and none is available from the market data supplied.

Analysis — what it means for markets and the ALRPD ticker

The practical read for holders of ALRPD is that the growth is described as organic expansion of an existing base rather than a single contract win. That matters because it implies the revenue run-rate could persist into Q4 if the operating base holds.

Second-order effects sit with the group's own channel structure. If proprietary products such as SystemLS® and practitioner services scale through the five wellness hubs, the revenue mix shifts toward company-owned lines rather than third-party distribution. The report does not quantify that mix, so the size of the shift is unknown.

The obvious limitation is verification. These are unaudited management numbers, not audited accounts, and the company explicitly flags them as subject to finalisation. A 1,000% growth claim against an undisclosed base is directionally striking but hard to stress-test without the FY2025 dollar figure.

A second counter-argument is durability. Management attributes the quarter to foundations laid in H1 2026, which implies the base was built with capital and operating spend. The report discloses nothing about the cost of building that base, so the reader cannot judge whether the revenue arrived efficiently.

Positioning-wise, the update is aimed at shareholders already holding the Euronext Growth Paris line. The company said it expects to provide further updates as it executes the strategy, which keeps the disclosure cadence in management's hands rather than on a fixed schedule.

Outlook — what to watch next

The next hard datapoint is the Q4 trading period, covering October through December 2026, and any subsequent update the company chooses to publish. No date for that update was given.

Investors should watch three things. First, whether average monthly revenue holds at or above the Q3 level, since the company only described momentum as encouraging rather than guiding to a number. Second, whether management converts the unaudited Q3 figure into audited full-period accounts. Third, whether SystemLS® and practitioner services are named individually in future updates, which would signal they are becoming material revenue lines.

The company did not disclose terms, volumes or pricing for any hub, brand or product line, so no level-based triggers can be set from this report. Statements about the remainder of H2 are management's current expectations and are not a forecast or guarantee of future revenue.

Frequently Asked Questions

What does Rapid Nutrition's Q3 2026 revenue update actually tell investors?

It tells investors that the company's own unaudited management information shows roughly $1 million in average monthly Group revenue for July to September 2026, which it says is more than 1,000% above the FY2025 monthly average. It does not disclose the absolute FY2025 monthly figure, the quarterly total, profit, margin or cash position, so the update confirms direction and scale rather than full financial performance.

Why is the percentage comparison against FY2025 rather than Q2 2026?

Rapid Nutrition chose its FY2025 average monthly Group revenue as the baseline, which the report states explicitly. That choice shows how far the business has travelled from its prior-year run-rate, but it does not show sequential quarter-on-quarter momentum. Investors wanting to judge whether growth is accelerating will need the Q2 2026 comparative, which the report does not provide.

What happens next for Rapid Nutrition shareholders?

The company said it expects to provide further updates as it continues to execute its accelerated growth strategy, without giving a date. Management's stated priorities are strengthening group operations, expanding SystemLS® and other proprietary products through available channels, and developing practitioner services at its wellness hubs. The revenue figures remain unaudited and subject to finalisation, so formal accounts are the next verification step.

Bottom Line

Rapid Nutrition's unaudited Q3 shows roughly $1 million in monthly revenue, over ten times its FY2025 average, but the undisclosed base and lack of audited figures leave the scale unverified.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.